Revised Prices of Anti-Cancer Medicines to Come into Effect from 9th November;

Ministry of Chemicals and Fertilizers :

Department of Pharmaceuticals Revised Prices of Anti-Cancer Medicines to Come into Effect from 9th November;

More than 1000 medicines of different brands show marked Price reduction;

Estimated annual savings to consumers expected to be above ₹3500 crore

Posted On: 07 NOV 2026 3:51PM by PIB Delhi National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, capped trade margins on MRP of 137 anti-cancer drugs, based on the recommendations of Expert Committee constituted by the Directorate General of Health Services (DGHS) under Ministry of Health & Family Welfare on 17th October, 2026. The revised prices of these drugs will come into effect from 9th November, 2026.

As on date, 76 pharmaceutical companies have reported revised MRP for 1225 anti-cancer formulations, covering 121 drugs. Reduction in the MRP have been reported in 1031 formulations of anti-cancer medicines, with 600 brands reporting above 50% reduction and the highest reduction being 96.45%. Further, out of the 137 identified anti-cancer drugs, there are 10-15 drugs which are yet to be launched in India. However, Trade Margin Rationalization (TMR) will be applicable on these drugs also as and when they are launched.

As a result of the price reductions to be effected from 9th November, 2026, the estimated annual savings to consumers would be ₹3,502.31 crore.

List of major anti-cancer brands with revised prices Formulation Brand Name Company Name Old MRP (₹) Revised MRP (₹)Bevacizumab Bryxta Zydus Lifesciences 25,995.00 3,318.0 100 MG Limited

Injection: Used for Lung, Colon, BevaciRel Reliance Life 24,079.00 3,985.0 Ovary and Sciences Private Cervical Cancer Limited CIZUMAB HETERO 15,658.00 3,103.0 HEALTHCARE LTD Versavo Dr. Reddys 7,686.00 3,504.2 Laboratories Limited Denosumab DenOsteoRel Reliance Life 24,955.00 6,240.0 60 MG Sciences Private

Injection: Limited Used for breast and Debrumab RPG LIFE SCIENCES 22,031.25 5,941.0 prostate LTD cancer (prevents Denoclast Zydus Lifesciences 19,687.50 7,334.8 bone loss) Limited ROZEL INTAS 15,458.40 6,825.5 PHARMACEUTICALS LTD Abiraterone ABIRONE ARVINCARE 41,250.00 3,218.2 acetate 250 PHARMA PVT LTD

MG Tablet:

Used for ABIRAT Khandelwal 36,088.81 4,064.4 Prostate Laboratories Cancer Private Limited AHABIR HETERO 33,876.50 4,925.0 HEALTHCARE LTD Abirapro Glenmark 28,744.00 5,768.0 Pharmaceuticals Ltd.Pegfilgrastim PEG FILTERO HETERO 9,093.00 1,631.0 6 MG HEALTHCARE LTD

Injection: To prevent Peg- Reliance Life 5,331.00 1,258.0 neutropenia ReliGrast Sciences Private in cancer Limited patients Pegex Gennova 6,270.45 1,527.7 Biopharmaceuticals Ltd.

Peg Frastim RPG LIFE SCIENCES 6,660.85 1,807.0 LTD Azacitidine AzatiRel Reliance Life 7,790.00 1,397.0 100 MG Sciences Private

Injection: Limited Used for Blood Cancer AZADINE INTAS 5,964.70 1,199.5 PHARMACEUTICALS LTD Azacytin Dr. Reddys 6,337.00 1,495.0 Laboratories Limited Azadual 100 MSN 4,852.03 1,207.8 LABORATORIES PRIVATE LIMITED Enzalutamide ENZAPTOR HALSTED PHARMA 20,625.00 2,475.6 40 MG 40 PVT LTD

Capsule:

Used for XTIDE ERIS LIFESCIENCES 10,828.12 1,729.2 prostate LIMITED cancer Enzuta Emcure 20,667.00 4,157.6 Pharmaceuticals Ltd.

ENZAMIDE INTAS 10,781.25 3,536.5 PHARMACEUTICALS LTDFulvestrant FASNORM ERIS LIFESCIENCES 30,421.87 3,671.7 250 mg LIMITED

Injection:

Used for FULZOS HETERO 16,500.00 3,215.0 breast cancer HEALTHCARE LTD Fulvira Emcure 16,694.95 3,900.4 Pharmaceuticals Ltd.

FISTENT INJ Adley Formulations 22,600.00 6,031.5 Pvt.Ltd Palbociclib Palbopro RPG LIFE SCIENCES 40,421.33 2,720.0 125 MG LTD

Capsule:

Used for PALBOMED Medicamen 13,500.00 2,302.0 breast cancer Biotech Limited PICLIB HETERO 7,801.50 2,058.0 HEALTHCARE LTD Palborest MSN 2,246.00 791.80 125 LABORATORIES PRIVATE LIMITED Pemetrexed ReliTrexed Reliance Life 9,977.00 1,113.0 500 MG Vial: Sciences Private Used for Limited lung cancer PEMETOMED Medicamen 5,062.00 940.00 Biotech Limited ADPEM 500 Adley Formulations 5,499.00 1,035.0 Pvt.Ltd Pemgem Dr. Reddys 7,032.00 3,408.6 Laboratories Limited Pertuzumab LUPIHER 2 Lupin Limited 83,520.00 37,358.

420 MG

Injection: Womab Dr. Reddys 74,992.50 53,708.

Used for Laboratories breast cancer LimitedTMR of non-scheduled anti-cancer medicines is an important step taken by the Government in its continued efforts to improve affordability and accessibility of essential anti-cancer medicines for cancer care.

The notification SO 5690 (E ) dated 17th October, 2026 will remain in force until further orders However, manufacturers can avail annual price increase in accordance with the provisions of Paragraph 20(1) of the Drugs (Prices Control) Order, 2013, subject to continued compliance with the maximum permissible trade margin of 30% Every retailer, dealer, hospital and institution is required to prominently display Revised MRP list of anti-cancer medicines on their websites and in their premises. As per the NPPA

notification, State Drug Controllers will monitor compliance by manufacturers, dealers, Hospitals and Medical Institutions. Consumers can check the applicable prices through the Pharma Sahi Daam mobile application and the NPPA website (www.nppa.gov.in) and report any non-compliance or violation of revised prices to the authority.

Complaints can be submitted through the following channels:

Email: monitoring-nppa[at]gov[dot]in

Helpline: 1800-11-1255

Post: Deputy Director, Monitoring, NPPA, 3rd Floor, YMCA Cultural Centre Building, 1 Jai Singh Marg, New Delhi – 110001. ***** PC/PM (Release ID: 2333949)Visitor Counter : 777

Read this release in: Urdu , Marathi , हन्दी , Bengali , Gujarati , Odia , Tamil , Kannada , Malayalam Share 723 words | 3 min read